Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors

Francesca Ceccherini-Silberstein, Kurt Van Baelen, Daniele Armenia, Maria Trignetti, Evelien Rondelez, Lavinia Fabeni, Fernanda Scopelliti, Michela Pollicita, Liesbeth Van Wesenbeeck, Veerle Van Eygen, Luca Dori, Loredana Sarmati, Stefano Aquaro, Guido Palamara, Massimo Andreoni, Lieven J. Stuyver, Carlo Federico Perno

Research output: Contribution to journalArticle

Abstract

The goal of this study was to explore the presence of integrase strand transfer inhibitor (InSTI) resistance mutations in HIV-1 quasispecies present in InSTI-naïve patients and to evaluate their in vitro effects on phenotypic susceptibility to InSTIs and their replication capacities. The RT-RNase H-IN region was PCR amplified from plasma viral RNA obtained from 49 HIV-1 subtype B-infected patients (21 drug naïve and 28 failing highly active antiretroviral therapy [HAART] not containing InSTIs) and recombined with an HXB2-based backbone with RT and IN deleted. Recombinant viruses were tested against raltegravir and elvitegravir and for replication capacity. Three-hundred forty-four recombinant viruses from 49 patients were successfully analyzed both phenotypically and genotypically. The majority of clones were not phenotypically resistant to InSTIs: 0/344 clones showed raltegravir resistance, and only 3 (0.87%) showed low-level elvitegravir resistance. No primary resistance mutations for raltegravir and elvitegravir were found as major or minor species. The majority of secondary mutations were also absent or rarely present. Secondary mutations, such as T97A and G140S, found rarely and only as minority quasispecies, were present in the elvitegravir-resistant clones. A novel mutation, E92G, although rarely found in minority quasispecies, showed elvitegravir resistance. Preexisting genotypic and phenotypic raltegravir resistance was extremely rare in InSTI-naïve patients and confined to only a restricted minority of secondary variants. Overall, these results, together with others based on population and ultradeep sequencing, suggest that at this point IN genotyping in all patients before raltegravir treatment may not be cost-effective and should not be recommended until evidence of transmitted drug resistance to InSTIs or the clinical relevance of IN minor variants/ polymorphisms is determined.

Original languageEnglish
Pages (from-to)3938-3948
Number of pages11
JournalAntimicrobial Agents and Chemotherapy
Volume54
Issue number9
DOIs
Publication statusPublished - Sep 2010

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Ceccherini-Silberstein, F., Van Baelen, K., Armenia, D., Trignetti, M., Rondelez, E., Fabeni, L., Scopelliti, F., Pollicita, M., Van Wesenbeeck, L., Van Eygen, V., Dori, L., Sarmati, L., Aquaro, S., Palamara, G., Andreoni, M., Stuyver, L. J., & Perno, C. F. (2010). Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrobial Agents and Chemotherapy, 54(9), 3938-3948. https://doi.org/10.1128/AAC.01720-09